A relatively high rate of CEACAM6-positive reactivity has been demonstrated in the sera of patients with lung cancer, hepatocellular carcinoma, pancreatic cancer, breast cancer, and colorectal cancer [10]. Here, CEACAM6 is linked to hepatocellular carcinoma.